Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10415 (
Bcl-2
)
33,771
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Endometrial carcinoma is one of the most frequently diagnosed cancers in females. Long non-coding RNAs (lncRNAs) have been associated with cancer; its role in endometrial carcinoma is an emerging area of research. In this article, lncRNA
TDRG1
expression in human endometrial carcinoma tissues and normal endometrial tissues was quantified by qRT-PCR. LncRNA
TDRG1
was overexpressed or knocked-down in neither HEC-1B nor Ishikawa endometrial carcinoma cells, respectively, to assess cellular phenotype and expression of related molecules. Our results showed that lncRNA
TDRG1
was significantly overexpressed in endometrial carcinoma tissues. Overexpression of lncRNA
TDRG1
promoted endometrial carcinoma cell viability, invasion and migratory ability, inhibited apoptosis, and upregulated VEGF-A, PI3K,
Bcl-2
, MMP2 and survivin; knockdown of lncRNA
TDRG1
had the opposite effects. LncRNA
TDRG1
overexpression increased tumorigenicity in vivo and was associated with the upregulation of VEGF-A. RNA binding protein immunoprecipitation (RIP) assays confirmed that lncRNA
TDRG1
directly binds to VEGF-A protein. Furthermore, knockdown of VEGFA in lncRNA
TDRG1
-overexpressing endometrial carcinoma cells reversed the effects of lncRNA
TDRG1
on cell proliferation, invasion, migration and apoptosis. In conclusion, lncRNA
TDRG1
may promote endometrial carcinoma cell proliferation and invasion by positively targeting VEGF-A and modulating relative genes.
...
PMID:LncRNA TDRG1 enhances tumorigenicity in endometrial carcinoma by binding and targeting VEGF-A protein. 2992 Mar 44